Horizon and Vidara to marry in a reverse merger

Horizon Pharma (HZNP) acquires Vidara Therapeutics in a cash-and-stock reverse merger valued at $660M.

74% of Horizon Pharma plc (the new company name) ordinary shares will be exchanged for Horizon Pharma Inc.'s common shares. Vidara will receive 26% of Horizon Pharma plc plus $200M cash.

Expected pro forma revenues for 2014 are $250M - $265M.

Timothy P. Walbert, Horizon Pharma Inc. Chairman, President and CEO will lead the new entity.

From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs